DAA Treatment and Hepatic Fibrosis Improvement in HCV: What's the Link?

Abstract

Presented at AASLD The Liver Meeting 2018. Study number 0603.

Kommineni VT et al.

Factors Associated with Lack of Improvement in Fibrosis Following HCV Treatment.

Monthly Prescribing Reference

DAA Treatment and Hepatic Fibrosis Improvement in HCV: What's the Link?

Cassandra Pardini, PharmD

According to the results of a prospective cohort study, 57% of patients with hepatitis C virus (HCV) infection who achieved sustained virologic response (SVR) showed no improvement in hepatic fibrosis. The study, which took place at a tertiary liver center, aimed to determine whether direct-acting antiviral (DAA) therapy reduced fibrosis and assessed whether any predictors of treatment failure existed at 1-year follow-up. A total of 193 patients were divided into 2 groups: those who achieved SVR (N=143) and those who failed treatment or did not receive it (N=50). 

Read More: https://www.empr.com/news/direct-acting-antivirals-fibrosis-staging-hepatitis-c-virus-predictors/article/814125/

Conference Articles

Direct-Acting Antiviral Therapy Linked to Reduced Risk of Incident T2D in HCV Patients 

By Cassandra Pardini, PharmD November 13, 2018